Avesthagen Limited on Monday announced that it has entered into a four-year strategic alliance with Wipro Limited for making its genetic testing portfolio commercial.

According to the company’s press statement, the portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.

The companies announced that they will execute the project titled, “Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer Project related Genomics Sequencing services.” The Project will be jointly led by Avesthagen and Wipro where Wipro’s state-of-the-art Life sciences lab will perform initial processing of the samples, generate data on the latest Next-generation sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML based tools, the companies claim…..READ MORE

POSTED BY News | Jun, 20, 2022 |